Passage Bio

📍 Philadelphia, United States🗓 Founded 2017👥 101 employees💰 Last funded Jul 2018
Biotechnology Research🌐 passagebio.com
Website LinkedIn
We are a genetics medicine company based in Philadelphia, PA, a city with a rich history of scientific discovery and medical advancement. As a leading developer of cutting-edge therapeutics for disorders of the central nervous system (CNS), we are proud to be a part of this dynamic research community. We are also excited about our new laboratory at the Princeton West Innovation Campus in Hopewell, New Jersey, which will help us evolve the standard for biotech innovation and development. At Passage Bio, we have a bold vision to fulfill the promise of gene therapy and a differentiated approach to gene therapy development through our collaboration with University of Pennsylvania's Gene Therapy Program and Orphan Disease Center. Our deep pipeline of optimized gene therapies for CNS disorders includes lead programs focused on the following devastating diseases: GM1 gangliosidosis Krabbe disease Frontotemporal dementia
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2017
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Passage Bio?
Passage Bio has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Passage Bio last raise funding?
The most recent investment in Passage Bio recorded on gritt.io was in July 2018.
When was Passage Bio founded?
Passage Bio was founded in 2017.
What industry is Passage Bio in?
Passage Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Passage Bio based?
Passage Bio is headquartered in Philadelphia, United States.